Skip to content
Screener

PTC Therapeutics PTCT Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$1.01M-47.3%
Scholar Rock logo
Scholar RockSRRK
$136K-90.2%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$1.37M+180%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$147K-86.1%

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.12B+81.1%
Enterprise value$5.68B+106%
P/E7.5×
P/S7.4×+5.5×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001070081-26-000012
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Unrealized loss on ClearPoint Equity Investments3,122
Unrealized gain on marketable securities - equity investments(1,214)(774)
Deferred income taxes(10)2
Amortization of discounts on investments, net(4,114)(2,313)
Amortization of debt issuance costs305299
Share-based compensation expense23,42118,060
Unrealized foreign currency transaction losses, net(887)2,251
Changes in operating assets and liabilities:

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's accretion (amortization) of discounts and premiums, investments?
PTC Therapeutics (PTCT) reported accretion (amortization) of discounts and premiums, investments of $4.11M in Q1 2026.
How has PTC Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
PTC Therapeutics's accretion (amortization) of discounts and premiums, investments increased by 77.9% year-over-year, from $2.31M to $4.11M.
What is the long-term trend for PTC Therapeutics's accretion (amortization) of discounts and premiums, investments?
Over 4 years (2021 to 2025), PTC Therapeutics's accretion (amortization) of discounts and premiums, investments has grown at a 35.8% compound annual growth rate (CAGR), from -$5.3M to $18.02M.
What does accretion (amortization) of discounts and premiums, investments mean?
Reflects the periodic adjustment to the carrying value of investment securities to reflect the amortization of premiums or accretion of discounts over the life of the instrument. This adjustment aligns the effective interest yield of the investment portfolio with the stated coupon rates.

Ask your AI about PTC Therapeutics's accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude